VEGFA and chronic kidney disease: When comparing the baseline characteristics, progression, and final outcomes based on the presence or absence of stage 3 CKD or higher (eGFR < 60) at baseline, no significant differences were observed in BCVA, CMT, or the number of anti-VEGF injections at any point (Table 3).